Bcl-xL Active human

recombinant, expressed in E. coli, ≥90% (SDS-PAGE)

BCL-XL/S, BCL2L1, Apoptosis regulator Bcl-X, Bcl-2-like protein 1
En este momento no podemos mostrarle ni los precios ni la disponibilidad

biological source



expressed in E. coli


≥90% (SDS-PAGE)


aqueous solution

mol wt

28 kDa


pkg of 100 μg

storage condition

avoid repeated freeze/thaw cycles


>0.02 mg/mL

NCBI accession no.

shipped in

dry ice

storage temp.


Gene Information

human ... BCL2L1(598)

General description

BCL2L1 (B-cell lymphoma 2 like 1) gene codes for the anti-apoptotic protein called Bcl-xL (B-cell lymphoma-extra large) and its isoform Bcl-xS. Bcl-xS functions as an antagonist of Bcl-xL. This gene is localized to human chromosome 20q11.21.


Useful for the study of apoptosis, screening inhibitors, and selectivity profiling.

Biochem/physiol Actions

BCL2L1 (B-cell lymphoma 2 like 1) or Bcl-xS functions as a dominant negative regulator of the anti-apoptotic isoform Bcl-xL. Bcl-xL is involved in modulating anti-apoptotic capacity of chemotherapy-resistant tumors. This protein is highly expressed in michigan cancer foundation 7 (MCF7) human breast carcinoma cells, and studies show that overexpression of Bcl-xS in these MCF-7 cells results in heightened sensitivity to chemotherapy-induced apoptosis by agents such as VP-16 or taxol.

Physical form

Formulated in 25 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.05% Tween-20, 30% glycerol and 3 mM DTT.

Preparation Note

Thaw on ice. Upon first thaw, briefly spin tube containing enzyme to recover full content of the tube. Aliquot enzyme into single use aliquots. Store remaining undiluted enzyme in aliquots at -70°C. Note: Enzyme is very sensitive to freeze/thaw cycles.
Certificado de Análisis
Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis.
Sumantran VN, et al.
Cancer Research, 55(12), 2507-2510 (1995)
Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation.
Keitel U, et al.
Oncotarget, 5(23), 11778-11791 (2014)
Gain of 20q11.21 in human embryonic stem cells improves cell survival by increased expression of Bcl-xL.
Nguyen HT, et al.
Molecular Human Reproduction, 20(2), 168-177 (2014)
BCL-XL mediates the strong selective advantage of a 20q11.21 amplification commonly found in human embryonic stem cell cultures.
Avery S, et al.
Stem Cell Reports, 1(5), 379-386 (2013)
Huntington's disease (HD) is an autosomal dominant, late-onset neurodegenerative disorder characterized by a selective neuronal cell death in the cortex and striatum leading to cognitive dysfunction, motor impairment and behavioral changes.
Más información

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.